EyePoint Pharmaceuticals, Inc.

NasdaqGM EYPT

EyePoint Pharmaceuticals, Inc. Net Income Margin for the Trailing 12 Months (TTM) ending September 30, 2024: -226.57%

EyePoint Pharmaceuticals, Inc. Net Income Margin is -226.57% for the Trailing 12 Months (TTM) ending September 30, 2024, a 20.55% change year over year. Net Income Ratio, also known as the profit margin, is the ratio of net income to net sales, showing the percentage of revenue that remains as profit after all expenses are deducted.

EyePoint Pharmaceuticals, Inc. Net Income Margin for the Trailing 12 Months (TTM) ending September 30, 2023 was -285.18%, a -51.55% change year over year.
EyePoint Pharmaceuticals, Inc. Net Income Margin for the Trailing 12 Months (TTM) ending September 30, 2022 was -188.18%, a -12.40% change year over year.
EyePoint Pharmaceuticals, Inc. Net Income Margin for the Trailing 12 Months (TTM) ending September 30, 2021 was -167.42%, a -49.17% change year over year.
EyePoint Pharmaceuticals, Inc. Net Income Margin for the Trailing 12 Months (TTM) ending September 30, 2020 was -112.23%, a 72.56% change year over year.

Key data

Date	Net Income Margin	EBITDA Margin	EBIT Margin	EBITDA

NasdaqGM: EYPT

EyePoint Pharmaceuticals, Inc.

CEO	Dr. Jay S. Duker M.D.
IPO Date	Jan. 27, 2005
Location	United States
Headquarters	480 Pleasant Street
Employees	121
Sector	Health Care
Industries Pharmaceuticals Eyewear

Description

EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for intravitreal injection for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; and DEXYCU, a dexamethasone intraocular suspension, for the treatment of post-operative ocular inflammation, including treatment following cataract surgery. It is also developing EYP-1901, a twice-yearly bioerodible formulation of tyrosine kinase inhibitor for the treatment of wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion; and YUTIQ50 for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. The company has strategic collaborations with Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics, and Equinox Science, LLC. It also has a commercial alliance with ImprimisRx PA, Inc. for the joint promotion of DEXYCU for the treatment of post-operative inflammation following ocular surgery. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.

Key trends

Past 5 years